Diffuse large B-cell lymphoma: open trials in Hong Kong SAR China

• NCT07200375

  An Observational Study of Glofitamab in Chinese Adult Participants With 2L Diffuse Large B-Cell Lymphoma

  Research · Hoffmann-La Roche

  Queen Mary Hospital, Hong Kong · Prince of Wales Hospital, Hong Kong

  Registry updated 2026-11-05

• NCT05139017

  A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

  Trial Treatment · Phase 2/3 · Merck Sharp & Dohme LLC

  Queen Mary Hospital ( Site 3100), Hong Kong · Princess Margaret Hospital ( Site 3101), Hong Kong

  Registry updated 2026-11-03

• NCT06717347

  A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

  Trial Treatment · Phase 3 · Merck Sharp & Dohme LLC

  Princess Margaret Hospital ( Site 3202), Hong Kong · Queen Mary Hospital ( Site 3201), Hong Kong

  Registry updated 2026-10-21

All Diffuse large B-cell lymphoma trials and the map

This page is not medical advice. Talk to your doctor before contacting a trial.

Report an error